CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the financing will be used to support commercialization of the BAROSTIM NEO in the United States ("US").

BAROSTIM NEO uses CVRx-patented technology, designed to send electrical pulses to baroreceptors located in the wall of the carotid artery, to deliver BAROSTIM THERAPY™.  The therapy is designed to restore balance to the autonomic nervous system and thereby improve the symptoms of HF. The BAROSTIM NEO is approved by FDA for HF in the US, and has received the CE Marking for HF and resistant hypertension in the European Economic Area.

CVRx® Raises $50 Million in New Equity Financing

Description

Company Information

Funding Insights

CVRx® Raises $50 Million in New Equity Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information